Misplaced Pages

This is the current revision of this page, as edited by Citation bot (talk | contribs) at 21:54, 30 November 2023 (Add: doi-access. | Use this bot. Report bugs. | Suggested by Neko-chan | #UCB_webform 110/200). The present address (URL) is a permanent link to this version.

Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.

References

1. Rondon E, Venkataraman R (August 2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care. 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.
2. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. (November 2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine. 32 (11): 2173–82. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628. S2CID 23321488.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Immunosuppressants
• Monoclonal antibody stubs
• Antineoplastic and immunomodulating drug stubs